Vivos Therapeutics, Inc.
VVOS Healthcare Medical Devices
Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 34.9%, EPS grew 43.6%, free cash flow grew 16.4% and total debt rose 2.79%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VVOS
Vivos Therapeutics, Inc. (VVOS) EV/Sales
As of 16 October 2026, Vivos Therapeutics, Inc. (VVOS) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from 0.1× (August 2024) to 12.3× (April 2021); the current reading is higher than 16% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | 37.10% |
| FY2024 | 1.2× | 7.48% |
| FY2023 | 1.1× | 8.19% |
| FY2022 | 1.0× | (33.15%) |
| FY2021 | 1.5× | (67.16%) |
| FY2020 | 4.5× | (48.23%) |
| FY2019 | 8.7× | 0.00% |
| FY2018 | 8.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | (40.67%) |
| Mar 2026 | 1.2× | (26.25%) |
| Dec 2025 | 1.6× | (30.72%) |
| Sep 2025 | 2.3× | 2.18% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation compare | −63.5× |
| CODX Co-Diagnostics, Inc. compare | −1.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| TBIO Telesis Bio Inc. compare | 0.1× |
| INBS Intelligent Bio Solutions Inc. compare | 0.2× |
| VVOS Vivos Therapeutics, Inc. | 0.4× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| VNRX VolitionRX Limited compare | 4.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)